



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

**Datasheet for 100-4164P****NFKB p50 (NFKB1) Peptide****Overview**

<b>Description:</b>	NFKB p50 (NFKB1) Peptide - 100-4164P
<b>Item No.:</b>	100-4164P
<b>Size:</b>	50 µg
<b>Origin:</b>	Human

**Product Details**

<b>Background:</b>	NFKB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a complex of protein subunits that ultimately control transcription of cellular response to stressful stimuli, such as: cytokine exposure, free radicals, UV and irradiation, bacterial and viral secretions, etc. NF-kB also assists in regulating the immune response to infection. When mis-regulated, NF-kB has been implicated in cancer, inflammation, autoimmune disorders, and insufficient clearing of viral infections.
<b>Synonyms:</b>	NFKB p50 Peptide, NFKB1 Peptide, DNA binding factor KBF1; DNA-binding factor KBF1; NF-kappabeta; nuclear factor NF-kappa-B p105 subunit; nuclear factor NF-kappa-B p50 subunit; nuclear factor kappa-B DNA binding subunit; NF-kB; NF-KB, control peptide, blocking peptide
<b>Species of Origin:</b>	Human
<b>Type:</b>	Peptide

**Target Details**

<b>Purity/Specificity:</b>	NFKB p50 (NFKB1) Control Peptide is greater than 95% specific peptide
<b>Relevant Links:</b>	<ul style="list-style-type: none"><li>• <a href="#">GeneID - 4790</a></li><li>• <a href="#">NCBI - CAB94757.1</a></li><li>• <a href="#">UniProtKB - P19838</a></li></ul>

**Application Details**

<b>Application Note:</b>	NFKB p50 (NFKB1) Control Peptide is intended for use as a control peptide when used with anti-Human NFKB p50 (NFKB1) to block specific interaction of anti-Human NFKB p50 (NFKB1) with
--------------------------	--

the Human NFkB p50 (NFKB1) subunit. NFKB p50 (NFKB1) Control Peptide should be used at 1.0 µg per 1.0 µl of antiserum in assay.

<b>Assay Dilutions:</b>	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
<b>ELISA:</b>	User Optimized
<b>IHC:</b>	User Optimized
<b>WB:</b>	User Optimized

## Formulation

<b>Physical State:</b>	Liquid (sterile filtered)
<b>Concentration:</b>	1.0 mg/mL by dry weight

## Shipping & Handling

<b>Shipping Condition:</b>	Dry Ice
<b>Storage Condition:</b>	Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. NFKB p50 (NFKB1) Control Peptide is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
<b>Expiration:</b>	Expiration date is six (6) months from date of receipt.

## Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

